Ebola vaccine study for healthy people in study communities
Part of Infections clinical trials.
This trial tests an Ebola vaccine in healthy people from local communities to see how it works and how safe it is. You may be able to join if you meet age, health, and vaccination/medication rules and can follow pregnancy-prevention and consent requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be in the study age range: 18–50 (Phase 1) or 6–65 (Phase 2)
- Have a permanent home address in the study communities
- Be able and willing to give consent (or assent if a child) and pass an understanding check
- Be judged healthy at screening (history, exam, and simple tests)
- If you could become pregnant, use effective birth control starting before vaccination and keep using it after vaccination
- If you have sex with women who could become pregnant, agree to use condoms or abstain as instructed after vaccination
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental vaccine designed to protect against Sudan virus, a rare but serious disease. Researchers will check if the vaccine is safe and helps your immune system fight off the virus.
This study tests a new mRNA vaccine (mRNA-1469) to prevent Ebola-Bundibugyo virus disease. It is for healthy adults to see if the vaccine is safe and produces an immune response.
This study tests whether it is safe and effective to give an Ebola vaccine at the same time as a COVID-19 booster shot. It may help find a way to protect against both diseases with fewer clinic visits.
This Phase 2 study compares Ebola vaccine immune responses when one Ebola treatment (Inmazeb) is given, then a vaccine (Ervebo) is given later. The goal is to see how the delay in timing changes your body’s immune response.
This study tests if a booster dose of one of two Ebola vaccines (Ervebo® or Zabdeno®) is safe and works well in people who already got an Ebola vaccine more than 4 months ago. It's especially for people living in the Democratic Republic of Congo (DRC) who may have been vaccinated before and might need a stronger, longer-lasting immune response.
This study tests a new malaria vaccine called PfSPZ-LARC2 in healthy adults living in Burkina Faso. If you qualify, the vaccine is given to see if it can protect you from malaria.
Hear when a new Sudan Ebola Virus Vaccines trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.